Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses

Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-15
DOI
https://doi.org/10.1038/s41467-026-79192-3
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses

Wei‐Yi Cheng, Jennifer Finney, Allen Y. Leary, Jacob Lowy et al.
Nature Communications
Immunotherapy and Immune Responses
article

Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses

Wei‐Yi Cheng, Jennifer Finney, Allen Y. Leary, Jacob Lowy, Frank A. Seebach, Kamilah Ryan, Dylan Kwart, Melissa Divya Mathias, Christopher Daly, Israel Lowy, Aynur Hermann, Lauric Haber, Jeremy S. Rabinowitz, Albert Canturri, Qiaozhi Wei, Erica Ullman, Jacqueline J. Warsaw, Dharani K. Ajithdoss, Patrick Poon, Andria Skinner, Jacquelynn Golubov, Erin Paul, William T. Poueymirou, Min Ni, Dimitris Skokos, Christina Adler, Bei Wang, Namita T. Gupta, Andrew J. Murphy, John C. Lin, Matthew Fury, Ciara Torres, Eric Smith, Nicole Stokes Oristian, William Olson
article en

Abstract

Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.

Nature Communications
Regeneron (United States) (US)
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon